Ahad Tariq
3 min read
We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Jasper Therapeutics, Inc. (JSPR) was one of the stocks that was covered in that article. Wall Street analysts believe JSPR has a 914% upside potential over the next 12 months.
A biotech scientist studying a microscope slide filled with hematopoietic stem cells.
Jasper Therapeutics, Inc. (NASDAQ:JSPR) is a clinical-stage biotechnology company that focuses on developing therapeutics targeting mast and hematopoietic stem cell-driven diseases. Its lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells.
JSPR focuses on the development and commercialization of therapeutic agents for patients with various mast cell-driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency.
In terms of marketing and distribution, Jasper Therapeutics, Inc. (NASDAQ:JSPR) has established exclusive licensing agreements with Amgen and Stanford University for the development and commercialization of briquilimab. These collaborations are crucial for advancing the company's product candidates and expanding its research capabilities. The company stated on its website:
"We have an exclusive license agreement with Amgen Inc. (“Amgen”) for the development and commercialization of the briquilimab monoclonal antibody in all indications and territories worldwide."
It must be noted that Jasper Therapeutics, Inc. (NASDAQ:JSPR) reported a net loss of $21.2 million for the first quarter of 2025, which was significantly higher than the previous year. This reflects increased operating expenses, primarily in research and development. The company’s cash balance stands at $49.2 million as of March 31, 2025. Meanwhile, operating expenses were higher at $15.1 million, with research and development expenses rising from $10.3 million to $16.2 million, both on a year-on-year comparison. Ronald Martell, President and Chief Executive Officer of Jasper spoke on the company’s performance:
“During the first quarter of 2025 we made great progress advancing briquilimab toward important data readouts later this year from all three of our clinical programs in mast cell diseases”.
On May 15, 2025, Oppenheimer analyst Jay Olson issued an update on Jasper Therapeutics (JSPR, Financial), reaffirming the firm's 'Outperform' rating for the company but revising the price target. Analysts on Wall Street following the stock hold an optimistic view of the company, with a “Strong Buy” rating and a consensus on the average price for the next twelve months estimated at $49.89, an upside of 914%.
